ID 4039 - Liściokwiat garbnikowy

PL: Liściokwiat garbnikowy
EN: Emblica officinalis (common name : Amla)
Pdf: various food(s)/food constituent(s) not supported by pertinent human data

Oświadczenie (2)

1.1. Przemiany substancji ksenobiotycznych (oczyszczanie organizmu, detoksykacja) (ID 1378, 2388, 2401, 3900, 3942, 4039, 4510, 4513, 4544, 4628, 4639)

The claimed effects are “purification”, “purifying/detoxifying”, “urinary elimination”, “depurative, detoxificant”, “detoxification”, “blood health”, “supports the natural mechanism for body's purification”, “elimination and detox”, and “favours toxin elimination”. The Panel assumes that the target population is the general population.
In the context of the proposed wordings and/or the clarifications provided by Member States, the Panel assumes that the claimed effect relates to the biotransformation of xenobiotic substances.
Enzymatic biotransformation reactions of xenobiotic substances after absorption involve Phase I and Phase II biotransformation reactions, which usually work together in a sequential manner to convert xenobiotics into more readily excretable metabolites (Yu, 2005; Buhler and Williams, 1988). Phase I biotransformation reactions include oxidation, reduction, and hydrolysis, while Phase II biotransformation consists essentially of conjugation reactions (Yu, 2005). Whereas biotransformation reactions normally result in detoxification, some chemicals may also be enzymatically converted to highly reactive, electrophilic metabolites which may induce cytotoxic, teratogenic, mutagenic or carcinogenic effects through reaction with various cellular constituents (Buhler and Williams, 1988).
The Panel notes that from the proposed wordings or the clarifications provided by Member States it could not be established which xenobiotic substance or which biotransformation reaction related to the elimination of xenobiotic substances is the target for the claim.
In the absence of such information, the Panel considers that the claimed effect is general and non- specific and does not refer to any specific health claim as required by Regulation (EC) No 1924/2006.

1.4. Utrzymanie prawidłowego funkcjonowania jelit (ID 4039)

The claimed effect is “elimination and detox”. The Panel assumes that the target population is the general population.
In the context of the clarification provided by Member States, the Panel assumes that the claimed effect is related to aspects of “laxative action”. Changes in bowel function within the normal range e.g. reduced transit time, increased frequency of bowel movements or bulk of stools might be interpreted as improvement of bowel function.
The Panel considers that maintenance of normal bowel function might be a beneficial physiological effect.

2.2. Utrzymanie prawidłowego funkcjonowania jelit (ID 4039)

The references provided included some textbooks in which the claimed effect was mentioned. The remaining references were animal or in vitro studies which were not related to the claimed effect. The Panel considers that no conclusions can be drawn from these references for the scientific substantiation of the claimed effect.
The Panel concludes that a cause and effect relationship has not been established between the consumption of the food/food constituent which is the subject of the health claim and maintenance of normal bowel function.

Warunki i możliwe ograniczenia stosowania oświadczenia

Powder 3-0.2 g/day; aqueous extra 1.5-0.1 g/day All over 2 years old: 2-4 years ¼ adult dose, 4-10 years half adult dose